Demographics of patients 70 years and older who received HCT from 2000 to 2013
| . | 2000-2007, n (%) . | 2008-2013, n (%) . | All patients, n (%) . |
|---|---|---|---|
| No. of patients | 207 | 899 | 1106 |
| No. of centers | 65 | 93 | 103 |
| Age at transplant, y | |||
| Median (range) | 72 (70-83) | 72 (70-84) | 72 (70-84) |
| 70-74 | 176 (85) | 807 (90) | 983 (89) |
| 75-79 | 27 (13) | 88 (10) | 115 (10) |
| ≥80 | 4 (2) | 4 (<1) | 8 (1) |
| Sex | |||
| Male | 151 (73) | 629 (70) | 780 (71) |
| Female | 56 (27) | 270 (30) | 326 (29) |
| KPS | |||
| <80% | 17 (8) | 87 (10) | 104 (9) |
| ≥80% | 119 (57) | 784 (87) | 903 (82) |
| Missing | 71 (34) | 28 (3) | 99 (9) |
| HCT-comorbidity index | |||
| 0 | — | 248 (28) | 248 (22) |
| 1-2 | — | 234 (26) | 234 (21) |
| ≥3 | — | 417 (46) | 417 (38) |
| Missing* | 207 | 0 | 207 (19) |
| Disease | |||
| AML | 103 (50) | 496 (55) | 599 (54) |
| ALL | 2 (<1) | 23 (3) | 25 (2) |
| CLL/PLL | 22 (11) | 54 (6) | 76 (7) |
| CML | 5 (2) | 6 (<1) | 11 (<1) |
| MDS/MPS | 32 (15) | 215 (24) | 247 (22) |
| Other acute leukemia | 1 (<1) | 8 (<1) | 9 (<1) |
| NHL | 23 (11) | 90 (10) | 113 (10) |
| Plasma cell disorder/multiple myeloma | 10 (5) | 2 (<1) | 12 (1) |
| Other malignancies | 3 (1) | 0 | 3 (<1) |
| Severe aplastic anemia | 4 (2) | 5 (<1) | 9 (<1) |
| PNH | 2 (1) | 0 | 2 (<1) |
| Disease status | |||
| Early disease | 45 (22) | 355 (39) | 300 (27) |
| Intermediate disease | 25 (12) | 93 (10) | 118 (11) |
| Advanced disease | 48 (23) | 230 (26) | 278 (25) |
| NHL sensitive | 10 (5) | 79 (10) | 89 (9) |
| NHL resistant | 6 (3) | 10 (1) | 16 (1) |
| Other (unknown/missing/NA) | 73 (35) | 132 (15) | 205 (19) |
| DRI† | |||
| Low | 6 (3) | 32 (4) | 38 (3) |
| Intermediate | 28 (14) | 152 (17) | 180 (16) |
| High | 20 (10) | 115 (13) | 135 (12) |
| Very high | 7 (3) | 18 (2) | 25 (2) |
| Other (missing/NA) | 146 (71) | 582 (65) | 728 (66) |
| Donor type | |||
| Matched related | 93 (45) | 204 (23) | 297 (27) |
| Mismatched related | 13 (6) | 67 (7) | 80 (7) |
| Matched unrelated | 52 (25) | 463 (52) | 515 (47) |
| Mismatched unrelated | 12 (6) | 68 (8) | 80 (7) |
| Unrelated HLA match unknown | 20 (10) | 46 (5) | 66 (6) |
| Umbilical cord blood | 7 (3) | 51 (6) | 58 (5) |
| Missing | 10 (5) | 0 | 10 (1) |
| Unrelated donor age, median (range), y | 36 (21-60) | 30 (19-61) | 31 (19-61) |
| 18-30 | 23 (27) | 278 (48) | 301 (46) |
| 31-40 | 24 (29) | 139 (24) | 163 (25) |
| 41-50 | 21 (25) | 96 (17) | 117 (18) |
| 51-61 | 5 (6) | 25 (4) | 30 (5) |
| Unknown | 11 (13) | 39 (7) | 50 (8) |
| Graft source | |||
| Bone marrow | 17 (8) | 93 (10) | 110 (10) |
| Peripheral blood | 183 (88) | 755 (84) | 938 (85) |
| Umbilical cord blood | 7 (3) | 51 (6) | 58 (5) |
| Donor–recipient sex match | |||
| Male–male | 95 (46) | 388 (43) | 483 (44) |
| Male–female | 25 (12) | 154 (17) | 179 (16) |
| Female–male | 50 (24) | 203 (23) | 253 (23) |
| Female–female | 30 (14) | 98 (11) | 128 (12) |
| Unknown | 7 (3) | 56 (6) | 63 (6) |
| Donor–recipient CMV status | |||
| Positive–positive | 16 (8) | 269 (30) | 285 (26) |
| Positive–negative | 7 (3) | 67 (7) | 74 (7) |
| Negative–positive | 37 (18) | 292 (32) | 329 (30) |
| Negative–negative | 13 (6) | 176 (20) | 189 (17) |
| Unknown | 134 (65) | 95 (11) | 229 (21) |
| Regimen intensity | |||
| Ablative | 11 (5) | 102 (11) | 113 (10) |
| RIC/NMA | 178 (86) | 796 (89) | 974 (88) |
| Unknown | 18 (9) | 1 (<1) | 19 (2) |
| Conditioning regimen | |||
| Flu/Bu ± other | 29 (14) | 368 (41) | 397 (36) |
| Flu/Mel ± other | 35 (17) | 137 (15) | 172 (16) |
| Flu/TBI ± other | 65 (31) | 274 (30) | 339 (31) |
| Bu based | 11 (5) | 17 (2) | 28 (3) |
| Flu/Cy ± other | 26 (13) | 40 (4) | 66 (6) |
| TBI/TLI ± other | 16 (8) | 49 (5) | 65 (6) |
| Other | 17 (8) | 14 (2) | 31 (3) |
| Unknown | 8 (4) | 0 | 8 (<1) |
| . | 2000-2007, n (%) . | 2008-2013, n (%) . | All patients, n (%) . |
|---|---|---|---|
| No. of patients | 207 | 899 | 1106 |
| No. of centers | 65 | 93 | 103 |
| Age at transplant, y | |||
| Median (range) | 72 (70-83) | 72 (70-84) | 72 (70-84) |
| 70-74 | 176 (85) | 807 (90) | 983 (89) |
| 75-79 | 27 (13) | 88 (10) | 115 (10) |
| ≥80 | 4 (2) | 4 (<1) | 8 (1) |
| Sex | |||
| Male | 151 (73) | 629 (70) | 780 (71) |
| Female | 56 (27) | 270 (30) | 326 (29) |
| KPS | |||
| <80% | 17 (8) | 87 (10) | 104 (9) |
| ≥80% | 119 (57) | 784 (87) | 903 (82) |
| Missing | 71 (34) | 28 (3) | 99 (9) |
| HCT-comorbidity index | |||
| 0 | — | 248 (28) | 248 (22) |
| 1-2 | — | 234 (26) | 234 (21) |
| ≥3 | — | 417 (46) | 417 (38) |
| Missing* | 207 | 0 | 207 (19) |
| Disease | |||
| AML | 103 (50) | 496 (55) | 599 (54) |
| ALL | 2 (<1) | 23 (3) | 25 (2) |
| CLL/PLL | 22 (11) | 54 (6) | 76 (7) |
| CML | 5 (2) | 6 (<1) | 11 (<1) |
| MDS/MPS | 32 (15) | 215 (24) | 247 (22) |
| Other acute leukemia | 1 (<1) | 8 (<1) | 9 (<1) |
| NHL | 23 (11) | 90 (10) | 113 (10) |
| Plasma cell disorder/multiple myeloma | 10 (5) | 2 (<1) | 12 (1) |
| Other malignancies | 3 (1) | 0 | 3 (<1) |
| Severe aplastic anemia | 4 (2) | 5 (<1) | 9 (<1) |
| PNH | 2 (1) | 0 | 2 (<1) |
| Disease status | |||
| Early disease | 45 (22) | 355 (39) | 300 (27) |
| Intermediate disease | 25 (12) | 93 (10) | 118 (11) |
| Advanced disease | 48 (23) | 230 (26) | 278 (25) |
| NHL sensitive | 10 (5) | 79 (10) | 89 (9) |
| NHL resistant | 6 (3) | 10 (1) | 16 (1) |
| Other (unknown/missing/NA) | 73 (35) | 132 (15) | 205 (19) |
| DRI† | |||
| Low | 6 (3) | 32 (4) | 38 (3) |
| Intermediate | 28 (14) | 152 (17) | 180 (16) |
| High | 20 (10) | 115 (13) | 135 (12) |
| Very high | 7 (3) | 18 (2) | 25 (2) |
| Other (missing/NA) | 146 (71) | 582 (65) | 728 (66) |
| Donor type | |||
| Matched related | 93 (45) | 204 (23) | 297 (27) |
| Mismatched related | 13 (6) | 67 (7) | 80 (7) |
| Matched unrelated | 52 (25) | 463 (52) | 515 (47) |
| Mismatched unrelated | 12 (6) | 68 (8) | 80 (7) |
| Unrelated HLA match unknown | 20 (10) | 46 (5) | 66 (6) |
| Umbilical cord blood | 7 (3) | 51 (6) | 58 (5) |
| Missing | 10 (5) | 0 | 10 (1) |
| Unrelated donor age, median (range), y | 36 (21-60) | 30 (19-61) | 31 (19-61) |
| 18-30 | 23 (27) | 278 (48) | 301 (46) |
| 31-40 | 24 (29) | 139 (24) | 163 (25) |
| 41-50 | 21 (25) | 96 (17) | 117 (18) |
| 51-61 | 5 (6) | 25 (4) | 30 (5) |
| Unknown | 11 (13) | 39 (7) | 50 (8) |
| Graft source | |||
| Bone marrow | 17 (8) | 93 (10) | 110 (10) |
| Peripheral blood | 183 (88) | 755 (84) | 938 (85) |
| Umbilical cord blood | 7 (3) | 51 (6) | 58 (5) |
| Donor–recipient sex match | |||
| Male–male | 95 (46) | 388 (43) | 483 (44) |
| Male–female | 25 (12) | 154 (17) | 179 (16) |
| Female–male | 50 (24) | 203 (23) | 253 (23) |
| Female–female | 30 (14) | 98 (11) | 128 (12) |
| Unknown | 7 (3) | 56 (6) | 63 (6) |
| Donor–recipient CMV status | |||
| Positive–positive | 16 (8) | 269 (30) | 285 (26) |
| Positive–negative | 7 (3) | 67 (7) | 74 (7) |
| Negative–positive | 37 (18) | 292 (32) | 329 (30) |
| Negative–negative | 13 (6) | 176 (20) | 189 (17) |
| Unknown | 134 (65) | 95 (11) | 229 (21) |
| Regimen intensity | |||
| Ablative | 11 (5) | 102 (11) | 113 (10) |
| RIC/NMA | 178 (86) | 796 (89) | 974 (88) |
| Unknown | 18 (9) | 1 (<1) | 19 (2) |
| Conditioning regimen | |||
| Flu/Bu ± other | 29 (14) | 368 (41) | 397 (36) |
| Flu/Mel ± other | 35 (17) | 137 (15) | 172 (16) |
| Flu/TBI ± other | 65 (31) | 274 (30) | 339 (31) |
| Bu based | 11 (5) | 17 (2) | 28 (3) |
| Flu/Cy ± other | 26 (13) | 40 (4) | 66 (6) |
| TBI/TLI ± other | 16 (8) | 49 (5) | 65 (6) |
| Other | 17 (8) | 14 (2) | 31 (3) |
| Unknown | 8 (4) | 0 | 8 (<1) |
ALL, acute lymphoblastic leukemia; Bu, busulfan; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; Flu/Bu, fludarabine + busulfan; Flu/Mel, fludarabine + melphalan; Flu/TBI, fludarabine + total body irradiation; MPS, myeloproliferative syndrome; NA, not available; PLL, prolymphocytic leukemia; PNH, paroxysmal nocturnal hemoglobinuria; Flu/Cy, fludarabine + cyclophosphamide; TBI/TLI, total body irradiation or total lymphoid irradiation.
HCT-comorbidity index was not captured by the CIBMTR registry prior to 2008.
All elements required to generate the DRI were not available in all patients.